Investors & Media Press Releases

Press Releases

Summary Toggle

04.16.2019

Summary Toggle Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Summary Toggle-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to be highlighted in poster presentation- BASEL, Switzerland , April 16, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

04.04.2019

Summary Toggle Axovant Announces Plan to Effect Reverse Share Split

Summary Toggle- Closing of $40 million financing with participation from leading shareholders - - 1-for-8 reverse share split expected in May 2019 - BASEL, Switzerland , April 04, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies,
Read More

PDF Version
Read More
Summary Toggle

03.29.2019

Summary Toggle Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies

Summary Toggle-R&D Day featuring leading physicians and scientists in Parkinson’s disease, GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs disease) will be webcast today at 8:30a.m. ET from New York - -Approximately 25% decrease in GM2 ganglioside in CSF observed at end of three-month period in the first
Read More

PDF Version
Read More
Summary Toggle

03.14.2019

Summary Toggle Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

Summary ToggleNEW YORK and BASEL, Switzerland , March 14, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its common shares at a price to the public of $1.50 per share.
Read More

PDF Version
Read More
Summary Toggle

03.13.2019

Summary Toggle Axovant Sciences Announces Public Offering of Common Shares

Summary ToggleNEW YORK and BASEL, Switzerland , March 13, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant.
Read More

PDF Version
Read More
Summary Toggle

03.11.2019

Summary Toggle Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease

Summary Toggle25-point (42%) mean improvement in the UPDRS Part III (motor) OFF score, with individual patient improvements of 14-points and 36-points respectively Benefit seen across all UPDRS OFF subscales at 3 months Reductions in ON state dyskinesias seen on the Rush Dyskinesia Rating Scale and diary ON time
Read More

PDF Version
Read More
Summary Toggle

03.11.2019

Summary Toggle Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy

Summary ToggleGenerally well-tolerated with no serious adverse events in a 30-month-old patient with advanced infantile Tay-Sachs disease Stable clinical condition from baseline to month 3 without deterioration on neurological exam Increase in CSF β-Hexosaminidase A enzyme activity from baseline to month 3,
Read More

PDF Version
Read More
Summary Toggle

03.04.2019

Summary Toggle Axovant to Present at Cowen and Company 39th Annual Health Care Conference

Summary ToggleNEW YORK and BASEL, Switzerland , March 04, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at the Cowen and Company 39th Annual Health Care
Read More

PDF Version
Read More
Summary Toggle

02.21.2019

Summary Toggle Axovant to Host First R&D Day March 29, 2019

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host its first R&D Day for investors and analysts in New York City on Friday, March 29, 2019 , beginning
Read More

PDF Version
Read More
Summary Toggle

02.19.2019

Summary Toggle Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in a fireside chat at the 8th Annual SVB Leerink
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search